• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
IMS Company Profiles:Novartis Product Image

IMS Company Profiles:Novartis

  • Published: April 2014
  • 108 Pages
  • IMS Health

IMS Company Profiles gives a clear picture of the companies' strengths in terms of therapy areas and relevant marketed products as well as the future strategic direction of companies including R&D pipelines, analysts forecasts and events predicted to impact the future.

Use IMS Company Profiles to:

- As a first step to any in-depth competitor analysis exercice
- Understand the influence of companies within therapy areas
- Evaluate the future drivers and potential constraints of companies
- Review independent analysts forecasts and commentaries
- Gain a comprehensive picture of a company's strategic direction

Corporate Structure

Strategy statement

Highlights a company's strengths / weaknesses and its potential for future growth. The strategy analysis gives you an insight into the following:

- M&A
- Regional strategies
- Therapeutic focus
- R&D strategy
- Licensing activities
- Commentary on future prospects, including brokers' overviews
- Interview with a key person (where available), including quotes and opinions
- Forecasting table (top 30 companies only), showing events with major potential impact

Financial Review

Company sales performance as well as analyst's comments and forecasts.

Company Sales Performance:

- Financial review
- Latest results
- Sales by geographical region & leading country
- Sales by country and subsidiary
- Analysis comments

Product Portfolio

Company Profiles reviews up to 40 products per company, whilst annual reports from the top 10 pharmaceutical companies cover up to a maximum of 10 drugs.

The section shows:

- Summary table of products facing patent expiry.
- Breakdown by relevant therapy area, within which, each product is discussed under the following headings: general, licensing, patents, clinical data, lifecycle management, competition and analysts' forecasts/comments.

R&D Pipelines

Comprehensive details of the projects that the company has in its R&D pipeline including:

- Research pipeline summary table.
- Introduction to the R&D activities of the company.
- Breakdown by relevant therapy area, within which, each project is detailed (up to 2 A4 pages), including information on clinical status and analysts' forecasts.
- Quotes from senior personnel gleaned from conferences may also be included in this section when available.

Key figures

- Sales by business segment.
- Sales by geographical region.

Analyst figures

IMS Sales data

- Pharmaceutical sales by geographical region and leading countries.
- Top 5 third level therapeutic classes.
- Leading international products
- Pharmaceutical sales analysis by age

Employee data

Licensing/Co-Marketing Agreements

Displayed in a tabular format to enable you to have “at a glance” review of the licensing activities of the company.

Three sections are available to review licensing activities:

- Marketed products
- R&D pipeline products
- General research collaborations, including combinatorial chemistry, proprietary technologies etc.

Major Events

Summary of the major events that have affected the company. This includes recent and historical events.

Two sections

- Mergers and Acquisitions
- Other major events

Events are organised in chronological order.

Subsidiaries listing

Mini-profile of each subsidiary that the company has worldwide showing address, major contacts and principal products.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

  • Novartis AG in Consumer Health (World) - Product Thumbnail Image Novartis AG in Consumer Health (World)

    Novartis AG in Consumer Health (World)

    • Language: English
    • Published: September 2013
    • Region: Global
    FROM
  • IMS Company Profiles:Boehringer Ingelheim - Product Thumbnail Image

    IMS Company Profiles:Boehringer Ingelheim

    • Language: English
    • 75 Pages
    • Published: August 2013
  • IMS Company Profiles:Daiichi Sankyo - Product Thumbnail Image IMS Company Profiles:Daiichi Sankyo

    IMS Company Profiles:Daiichi Sankyo

    • Language: English
    • 79 Pages
    • Published: July 2013
  • IMS Company Profiles:Ipsen - Product Thumbnail Image IMS Company Profiles:Ipsen

    IMS Company Profiles:Ipsen

    • Language: English
    • 50 Pages
    • Published: July 2013
  • IMS Company Profiles:Eisai - Product Thumbnail Image IMS Company Profiles:Eisai

    IMS Company Profiles:Eisai

    • Language: English
    • 74 Pages
    • Published: February 2013
  • IMS Company Profiles:PAR Pharmaceuticals - Product Thumbnail Image

    IMS Company Profiles:PAR Pharmaceuticals

    • Language: English
    • 29 Pages
    • Published: August 2013
  • IMS Company Profiles:Apotex - Product Thumbnail Image

    IMS Company Profiles:Apotex

    • Language: English
    • 30 Pages
    • Published: August 2013
  • IMS Company Profiles:Leo Pharma - Product Thumbnail Image IMS Company Profiles:Leo Pharma

    IMS Company Profiles:Leo Pharma

    • Language: English
    • 29 Pages
    • Published: July 2013
  • IMS Company Profiles:Zydus Cadila - Product Thumbnail Image IMS Company Profiles:Zydus Cadila

    IMS Company Profiles:Zydus Cadila

    • Language: English
    • 37 Pages
    • Published: July 2013
  • IMS Company Profiles:Galderma - Product Thumbnail Image IMS Company Profiles:Galderma

    IMS Company Profiles:Galderma

    • Language: English
    • 33 Pages
    • Published: September 2013